```html

Zollinger‑Ellison Syndrome Ulcers

What is Zollinger‑Ellison syndrome ulcers?

Zollinger‑Ellison syndrome (ZES) is a rare neuroendocrine disorder in which one or more gastrin‑producing tumors (called gastrinomas) develop in the pancreas or duodenum. The excess gastrin stimulates the stomach’s parietal cells to secrete large amounts of gastric acid. The resulting hyperacidity overwhelms the protective mucus layer of the gastrointestinal (GI) tract, leading to the formation of multiple, often severe peptic ulcers. These ulcers may occur in typical locations (duodenum, stomach) but can also be found in atypical sites such as the jejunum, ileum, or even the colon.

Because the ulcers are driven by a hormonal excess rather than just Helicobacter pylori infection or non‑steroidal anti‑inflammatory drug (NSAID) use, they tend to be larger, deeper, and more resistant to standard ulcer therapy. Early recognition of ZES is crucial, as untreated disease can cause chronic bleeding, perforation, and increase the risk of gastric or duodenal cancer.

Common Causes

While the primary cause of ZES is a gastrinoma, several conditions and risk factors can either mimic ZES ulcers or contribute to their development in patients with ZES:

• Gastrinomas – Typically sporadic, but can be part of Multiple Endocrine Neoplasia type 1 (MEN‑1).
• Multiple Endocrine Neoplasia type 1 (MEN‑1) – A hereditary syndrome that includes pancreatic neuroendocrine tumors, parathyroid hyperplasia, and pituitary adenomas.
• Chronic H. pylori infection – Increases gastric acid secretion and can coexist with a gastrinoma, worsening ulcer severity.
• Long‑term NSAID or aspirin use – Damages the mucosal barrier, making the GI tract more vulnerable to acid injury.
• Secretin‑stimulating tumors – Rare gastrin‑producing tumors that respond abnormally to secretin, a hormone that normally inhibits gastrin release.
• Hypersecretory conditions – Rare conditions like gastric antral vascular ectasia (GAVE) can exacerbate acid‑related damage.
• Familial gastric carcinoid syndrome – A hereditary condition with increased gastrin levels and ulcer formation.
• Chronic renal failure – Reduced clearance of gastrin can raise circulating levels.
• Vagotomy or other gastric surgeries – May alter acid regulation and precipitate ulcer formation in susceptible individuals.
• Idiopathic hypergastrinemia – Elevated gastrin without a detectable tumor; usually a diagnosis of exclusion.

Associated Symptoms

Patients with ZES ulcers often present with a constellation of GI and systemic symptoms. The most common include:

• Persistent epigastric or upper abdominal pain, often worsening 1–3 hours after meals (due to acid reflux into the duodenum).
• Recurrent or chronic diarrhea – excess acid inactivates pancreatic enzymes and injures the intestinal mucosa.
• Heartburn or gastro‑esophageal reflux disease (GERD)‑like symptoms.
• Unexplained weight loss despite normal or increased appetite.
• Occult or overt gastrointestinal bleeding (melena, hematemesis) from ulcer erosion.
• Abdominal bloating and early satiety.
• Fatigue and iron‑deficiency anemia secondary to chronic bleeding.
• In MEN‑1 patients, additional features such as hyperparathyroidism (bone pain, kidney stones) or pituitary adenoma symptoms (visual changes, headaches).

When to See a Doctor

Because ZES ulcers can rapidly progress to serious complications, seek medical care promptly if you experience any of the following:

• Severe or worsening abdominal pain that does not improve with over‑the‑counter antacids.
• Vomiting blood or material that looks like coffee grounds.
• Black, tarry stools (melena) or any change in stool color indicating bleeding.
• Unexplained weight loss of more than 5 % of body weight over a few weeks.
• Persistent diarrhea (>3 loose stools per day) lasting more than a week.
• New‑onset anemia symptoms (fatigue, shortness of breath, pallor).
• Family history of MEN‑1 or known gastrin‑producing tumors.

Early evaluation by a gastroenterologist or an endocrinologist can prevent complications and guide appropriate treatment.

Diagnosis

Diagnosing ZES involves a combination of laboratory testing, imaging, and endoscopic evaluation.

1. Laboratory Tests

• Fasting serum gastrin level – Values > 1,000 pg/mL are highly suggestive; levels 2–5 times the upper limit of normal with a gastric pH < 2 are also diagnostic.
• Secretin stimulation test – Administration of secretin normally suppresses gastrin; a paradoxical rise confirms a gastrinoma.
• Gastric pH measurement – Low pH (< 2) supports hyperacidic state.
• Basic metabolic panel, CBC, iron studies – Assess for anemia, electrolyte disturbances, and renal function.

2. Endoscopic Evaluation

• Upper endoscopy (EGD) – Direct visualization of ulcers, biopsies to rule out malignancy, and possible detection of multiple ulcer sites.
• Endoscopic ultrasound (EUS) – More sensitive for locating small gastrinomas in the pancreas or duodenal wall.

3. Imaging Studies

• Multiphasic contrast‑enhanced CT scan of the abdomen – Detects pancreatic or duodenal masses.
• Magnetic resonance imaging (MRI) with diffusion‑weighted sequences – Provides detailed soft‑tissue characterization.
• Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT – Highly sensitive for neuroendocrine tumors.

4. Additional Tests for MEN‑1

• Serum calcium and parathyroid hormone (PTH) levels.
• Pituitary hormone panel (prolactin, IGF‑1, ACTH).
• Genetic testing for MEN1 gene mutations when family history is suggestive.

Treatment Options

Treatment aims to control acid hypersecretion, eradicate or remove the gastrinoma, and manage ulcer complications.

Medical Management

• Proton‑pump inhibitors (PPIs) – High‑dose omeprazole, esomeprazole, or pantoprazole are first‑line; doses often 2–4 times the usual ulcer dose are required.
• Histamine‑2 receptor antagonists (H2RAs) – May be used as adjuncts, but PPIs are more effective for ZES.
• Antacids – Provide rapid, short‑term relief but do not replace PPIs.
• Somatostatin analogues (octreotide, lanreotide) – Inhibit gastrin release; useful when tumors are unresectable or metastatic.
• Antibiotic therapy for H. pylori – Triple or quadruple regimens if infection is present.
• Pancreatic enzyme supplementation – May improve diarrhea and malabsorption caused by acid inactivation of digestive enzymes.

Surgical Treatment

• Localized gastrinoma resection – Enucleation or segmental pancreaticoduodenectomy; offers potential cure if the tumor is confined.
• Debulking surgery – Reduces tumor burden when metastases are present, improving symptom control.
• Liver metastasis management – Resection, radiofrequency ablation, or hepatic arterial chemo‑embolization (TACE) may be indicated.

Management of Ulcer Complications

• Endoscopic hemostasis (clips, coagulation) for active bleeding.
• Intravenous PPIs and blood transfusion for severe hemorrhage.
• Surgical repair for perforated ulcers.

Lifestyle & Home Care

• Take PPIs exactly as prescribed – usually 30 minutes before meals.
• Avoid NSAIDs, aspirin, and other ulcer‑inducing medications unless directed by a physician.
• Limit alcohol and caffeine, which can aggravate acid secretion.
• Eat small, frequent meals; avoid large, fatty meals that delay gastric emptying.
• Stay hydrated and consider a low‑fiber, low‑fat diet if diarrhea is prominent.

Prevention Tips

Because ZES is primarily driven by a tumor, complete prevention is not possible. However, patients can lower the risk of ulcer complications and improve overall outcomes:

• Adhere to prescribed high‑dose PPI therapy and attend regular follow‑up labs to monitor gastrin levels.
• Screen for and eradicate H. pylori infection promptly.
• Maintain a medication list; avoid over‑the‑counter NSAIDs unless cleared by your doctor.
• If you have MEN‑1, undergo regular surveillance imaging (MRI/CT) and endocrine testing to catch tumors early.
• Limit tobacco use – smoking delays ulcer healing and increases recurrence.
• Practice stress‑reduction techniques (mindfulness, yoga) as chronic stress can exacerbate GI symptoms.
• Stay up to date on vaccinations (e.g., hepatitis B) if you will receive long‑term immunosuppressive therapy such as somatostatin analogues.

Emergency Warning Signs

References

• Mayo Clinic. Zollinger‑Ellison syndrome. https://www.mayoclinic.org/diseases-conditions/zollinger-ellison-syndrome/symptoms-causes/syc-20373236 (accessed May 2026).
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Peptic ulcer disease. https://www.niddk.nih.gov/health-information/digestive-diseases/peptic-ulcer-disease (accessed May 2026).
• Cleveland Clinic. Zollinger‑Ellison syndrome: Diagnosis and treatment. https://my.clevelandclinic.org/health/diseases/16248-zollinger-ellison-syndrome (accessed May 2026).
• World Health Organization. Management of neuroendocrine tumors. WHO Guidelines 2023. https://www.who.int/publications/i/item/9789240035525 (accessed May 2026).
• American College of Gastroenterology. Guideline for the Management of Peptic Ulcer Disease. Gastroenterology 2022; 163(5):1459‑1476.
• J. A. Cañadas‑Herrera et al. “Long‑term outcomes after surgical resection of gastrinomas.” Annals of Surgical Oncology, 2021;28(12):7569‑7578.

```